CEP55 overexpression predicts poor prognosis in patients with locally advanced esophageal squamous cell carcinoma

Jiang,Wenpeng; Wang,Zhou; Jia,Yang

doi:10.3892/ol.2016.5414

CEP55 overexpression predicts poor prognosis in patients with locally advanced esophageal squamous cell carcinoma

Authors:
- Wenpeng Jiang
- Zhou Wang
- Yang Jia
View Affiliations

Affiliations: Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: November 22, 2016 https://doi.org/10.3892/ol.2016.5414
Pages: 236-242
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Development of esophageal squamous cell carcinoma (ESCC) involves alterations in multiple genes with corresponding proteins. Recent studies have demonstrated that centrosomal protein 55 (CEP55) shares certain features with oncogenes, and CEP55 overexpression is associated with the development and progression of malignant tumors. The present study aimed to analyze, for the first time, whether CEP55 expression is related to clinicopothalogic features in the esophageal squamous cell carcinoma (ESCC), as well as patient survival. A total of 110 patients with mid‑thoracic ESCC who suffered from Ivor‑Lewis were enrolled. The CEP55 expression profile of these patients in tumour tissues and corresponding healthy esophageal mucosa (CHEM) was detected by immunohistochemistry and semi‑quantitative reverse transcription‑polymerase chain reaction analyses. Correlations between CEP55 expression and clinicopathological factors were analyzed using χ2 test. The log‑rank test was employed to calculate survival rate. A Cox regression multivariate analysis was performed to determine independent prognostic factors. The results demonstrated that CEP55 expression in ESCC was significantly higher than that of CHEM (P<0.001). Overexpression of CEP55 was significantly associated with differentiation degree (P=0.022), T stage (P=0.019), lymph node metastasis (P=0.033), clinicopathological staging (P=0.002) and tumor recurrence (P=0.021) in locally advanced ESCC patients. In addition, CEP55 overexpression was significantly associated with reduced overall survival of patients after surgery (P=0.012). The 5‑year survival rate of patients without CEP55 overexpression was significantly higher than that of patients with CEP55 overexpression (P=0.012). Therefore, these findings suggest that CEP55 overexpression correlates with poor prognosis in locally advanced ESCC patients.

View Figures

View References

1	Valverde CM, Macarulla T, Casado E, Ramos FJ, Martinelli E and Tabernero J: Novel targets in gastric and esophageal cancer. Crit Rev Oncol Hematol. 59:128–138. 2006. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T and Hatakeyama K: Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 198:205–211. 2004. View Article : Google Scholar : PubMed/NCBI
4	D'Annoville T, D'Journo XB, Loundou A, Trousse D, Dahan L, Doddoli C, Seitz JF and Thomas PA: Prognostic impact of the extracapsular lymph node involvement on disease-free survival according to the 7th edition of American joint committee on cancer staging system. Eur J Cardiothorac Surg. 44:e207–e211; discussion e211. 2013. View Article : Google Scholar : PubMed/NCBI
5	Hou X, Wei JC, Fu JH, Wang X, Zhang LJ, Lin P and Yang HX: Proposed modification of the seventh American joint committee on cancer staging system for esophageal squamous cell carcinoma in Chinese patients. Ann Surg Oncol. 21:337–342. 2014. View Article : Google Scholar : PubMed/NCBI
6	Song Y, Wang Z, Liu X, Jiang W and Shi M: CCR7 and VEGF-C: Molecular indicator of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy? Ann Surg Oncol. 19:3606–3612. 2012. View Article : Google Scholar : PubMed/NCBI
7	Fabbro M, Zhou BB, Takahashi M, Sarcevic B, Lal P, Graham ME, Gabrielli BG, Robinson PJ, Nigg EA, Ono Y and Khanna KK: Cdk1/Erk2- and Plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis. Dev Cell. 9:477–488. 2005. View Article : Google Scholar : PubMed/NCBI
8	Morita E, Sandrin V, Chung HY, Morham SG, Gygi SP, Rodesch CK and Sundquist WI: Human ESCRT and ALIX proteins interact with proteins of the midbody and function in cytokinesis. EMBO J. 26:4215–4227. 2007. View Article : Google Scholar : PubMed/NCBI
9	Zhao WM, Seki A and Fang G: Cep55, a microtubule-bundling protein, associates with centralspindlin to control the midbody integrity and cell abscission during cytokinesis. Mol Biol Cell. 17:3881–3896. 2006. View Article : Google Scholar : PubMed/NCBI
10	Sakai M, Shimokawa T, Kobayashi T, Matsushima S, Yamada Y, Nakamura Y and Furukawa Y: Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor. Oncogene. 25:480–486. 2006.PubMed/NCBI
11	Chen CH, Lu PJ, Chen YC, Fu SL, Wu KJ, Tsou AP, Lee YC, Lin TC, Hsu SL, Lin WJ, et al: FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway. Oncogene. 26:4272–4283. 2007. View Article : Google Scholar : PubMed/NCBI
12	Inoda S, Hirohashi Y, Torigoe T, Nakatsugawa M, Kiriyama K, Nakazawa E, Harada K, Takasu H, Tamura Y, Kamiguchi K, et al: Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. J Immunother. 32:474–485. 2009. View Article : Google Scholar : PubMed/NCBI
13	Chen CH, Chien CY, Huang CC, Hwang CF, Chuang HC, Fang FM, Huang HY, Chen CM, Liu HL and Huang CY: Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene. 28:2723–2737. 2009. View Article : Google Scholar : PubMed/NCBI
14	Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, et al: VEGFA up-regulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One. 4:e50522009. View Article : Google Scholar : PubMed/NCBI
15	Chang YC, Chen YJ, Wu CH, Wu YC, Yen TC and Ouyang P: Characterization of centrosomal proteins Cep55 and pericentrin in intercellular bridges of mouse testes. J Cell Biochem. 109:1274–1285. 2010.PubMed/NCBI
16	Tao J, Zhi X, Tian Y, Li Z, Zhu Y, Wang W, Xie K, Tang J, Zhang X, Wang L and Xu Z: CEP55 contributes to human gastric carcinoma by regulating cell proliferation. Tumour Biol. 35:4389–4399. 2014. View Article : Google Scholar : PubMed/NCBI
17	Talsma K, van Hagen P, Grotenhuis BA, Steyerberg EW, Tilanus HW, van Lanschot JJ and Wijnhoven BPL: Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer. Ann Surg Oncol. 19:2142–2148. 2012. View Article : Google Scholar : PubMed/NCBI
18	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
19	Dresner SM and Griffin SM: Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg. 87:1426–1433. 2000. View Article : Google Scholar : PubMed/NCBI
20	Tanabe G, Baba M, Kuroshima K, Natugoe S, Yoshinaka H, Aikou T and Kajisa T: Clinical evaluation of the esophageal lymph flow system based on RI uptake of dissected regional lymph nodes following lymphoscintigraphy. Nihon Geka Gakkai Zasshi. 87:315–323. 1986.(In Japanese). PubMed/NCBI
21	Chen G, Wang Z, Liu XY, Zhang MY and Liu FY: Abdominal lymph node metastasis in patients with mid thoracic esophageal squamous cell carcinoma. World J Surg. 33:278–283. 2009. View Article : Google Scholar : PubMed/NCBI
22	Li B, Chen H, Xiang J and Zhang Y, Li C, Hu H and Zhang Y: Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single-institution experience. J Thorac Cardiovasc Surg. 144:778–785; discussion 785–786. 2012. View Article : Google Scholar : PubMed/NCBI
23	Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, Komaki RR, Rashid A, Hamilton SR and Wu TT: The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 106:1017–1025. 2006. View Article : Google Scholar : PubMed/NCBI
24	Natsugoe S, Yoshinaka H, Shimada M, Sakamoto F, Morinaga T, Nakano S, Kusano C, Baba M, Takao S and Aikou T: Number of lymph node metastases determined by presurgical ultrasound and endoscopic ultrasound is related to prognosis in patients with esophageal carcinoma. Ann Surg. 234:613–618. 2001. View Article : Google Scholar : PubMed/NCBI
25	Baba M, Aikou T, Natsugoe S, Kusano C, Shimada M, Nakano S, Fukumoto T and Yoshinaka H: Quality of life following esophagectomy with three-field lymphadenectomy for carcinoma, focusing on its relationship to vocal cord palsy. Dis Esophagus. 11:28–34. 1998.PubMed/NCBI
26	Matsubara T, Ueda M, Takahashi T, Nakajima T and Nishi M: Localization of recurrent disease after extended lymph node dissection for carcinoma of the thoracic esophagus. J Am Coll Surg. 182:340–346. 1996.PubMed/NCBI
27	Yu Y, Wang Z, Liu XY, Zhu XF and Chen QF: Therapeutic efficacy comparison of two surgical procedures to treat middle thoracic esophageal carcinoma. World J Surg. 34:272–276. 2010. View Article : Google Scholar : PubMed/NCBI
28	Chen H, Wang Z, Yang Z, Shang B, Liu X and Chen G: Prospective study of adjuvant radiotherapy on preventing lymph node metastasis after Ivor-lewis esophagectomy in esophageal cancer. Ann Surg Oncol. 20:2721–2726. 2013. View Article : Google Scholar : PubMed/NCBI
29	Gromley A, Yeaman C, Rosa J, Redick S, Chen CT, Mirabelle S, Guha M, Sillibourne J and Doxsey SJ: Centriolin anchoring of exocyst and SNARE complexes at the midbody is required for secretory-vesicle-mediated abscission. Cell. 123:75–87. 2005. View Article : Google Scholar : PubMed/NCBI
30	Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT and Pellman D: Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature. 437:1043–1047. 2005. View Article : Google Scholar : PubMed/NCBI
31	Glotzer M: The molecular requirements for cytokinesis. Science. 307:1735–1739. 2005. View Article : Google Scholar : PubMed/NCBI
32	Paweletz N: Walther flemming: Pioneer of mitosis research. Nat Rev Mol Cell Biol. 2:72–75. 2001. View Article : Google Scholar : PubMed/NCBI
33	Carlton JG and Martin-Serrano J: Parallels between cytokinesis and retroviral budding: A role for the ESCRT machinery. Science. 316:1908–1912. 2007. View Article : Google Scholar : PubMed/NCBI
34	Sakai M, Shimokawa T, Kobayashi T, Matsushima S, Yamada Y, Nakamura Y and Furukawa Y: Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor. Oncogene. 25:480–486. 2006.PubMed/NCBI